Maxim Group Issues Negative Estimate for Scienture Earnings

Scienture Holdings, Inc. (NASDAQ:SCNX) – Analysts at Maxim Group cut their Q3 2026 EPS estimates for Scienture in a note issued to investors on Thursday, October 29th. Maxim Group analyst N. Rahman now anticipates that the company will post earnings per share of ($1.57) for the quarter, down from their previous forecast of ($1.50). Maxim Group currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Scienture’s current full-year earnings is ($5.75) per share. Maxim Group also issued estimates for Scienture’s Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($4.44) EPS and FY2027 earnings at ($0.27) EPS.

Scienture (NASDAQ:SCNX) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.25) by $2.18. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $1.96 million.

A number of other research firms have also weighed in on SCNX. Zacks Research raised shares of Scienture to a “hold” rating in a research report on Friday, October 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Scienture Price Performance

NASDAQ SCNX opened at $3.23 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.97 and a current ratio of 3.04. The stock’s 50-day moving average is $6.17 and its two-hundred day moving average is $9.17. Scienture has a fifty-two week low of $2.64 and a fifty-two week high of $27.75.

Institutional Trading of Scienture

A hedge fund recently bought a new stake in Scienture stock. Susquehanna International Group LLP acquired a new stake in Scienture Holdings, Inc. (NASDAQ:SCNX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture as of its most recent filing with the SEC. 5.68% of the stock is currently owned by hedge funds and other institutional investors.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. The company seeks to address unmet treatment needs through pharmaceutical products and drug-delivery technologies designed to improve patient convenience and therapeutic use.

Scienture’s areas of interest include conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. Its portfolio includes product candidates and commercial opportunities involving alternative delivery formats, including oral formulations and sprays.

The company serves the pharmaceutical market primarily in the United States.